Research Programme: antineoplastic monoclonal antibodies - Morphotek/John Wayne Cancer Institute

Drug Profile

Research Programme: antineoplastic monoclonal antibodies - Morphotek/John Wayne Cancer Institute

Latest Information Update: 27 Apr 2007

Price : $50

At a glance

  • Originator John Wayne Cancer Institute; Morphotek
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Lung cancer; Malignant melanoma; Solid tumours

Most Recent Events

  • 17 Apr 2007 Eisai acquires Morphotek
  • 30 Mar 2007 Preclinical development is ongoing
  • 18 Nov 2005 Preclinical trials in Solid tumours in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top